Table 2.
Clinical features of patients with RDD mimic IgG4-RD, RDD or IgG4-RD
| RDD mimic IgG4-RD (%) | RDD (%) | RDD total (%) | IgG4-RD (%) | p valuea | |
|---|---|---|---|---|---|
| Age (years) | 56(29–63) | 52.5(28–81) | 52.5(28–81) | 54(21–75) | – |
| Sex (M/F) | 7/0 | 7/3 | 14/3 | 21/13 | – |
| Site of involvement | |||||
| Lacrimal and salivary glands (LSG) | 2/7(28.6) | 1/10(10.0) | 3/17(17.6) | 21/34(61.8) | 0.0065 |
| Lymph node | 1/7(14.3) | 5/10(50.0) | 6/17(35.3) | 20/34(58.8) | 0.1441 |
| Pancreas | 1/7(14.3) | 0/10(0.0) | 1/17(5.9) | 8/34(23.5) | 0.2412 |
| Liver | 1/7(14.3) | 0/10(0.0) | 1/17(5.9) | 1/34(2.9) | > 0.9999 |
| Endocranium, dura mater, sellar region | 5/7(71.4) | 1/10(10.0) | 6/17(35.5) | 1/34(2.9) | 0.0038 |
| Retroperitoneum | 0/7(0.0) | 0/10(0.0) | 0/17(0.0) | 4/34(11.8) | 0.2876 |
| Skin | 1/7(14.3) | 1/10(10.0) | 2/17(11.8) | 1/34(2.9) | 0.5420 |
M, male; F, female
aMann–Whitney test between RDD total and IgG4-RD. RDD total group includes all the patients in RDD mimic IgG4-RD group and RDD group